Logo image of KRYS

KRYSTAL BIOTECH INC (KRYS) Stock Fundamental Analysis

NASDAQ:KRYS - Nasdaq - US5011471027 - Common Stock - Currency: USD

143.62  +6.08 (+4.42%)

After market: 143.62 0 (0%)

Fundamental Rating

6

Overall KRYS gets a fundamental rating of 6 out of 10. We evaluated KRYS against 550 industry peers in the Biotechnology industry. KRYS has an excellent financial health rating, but there are some minor concerns on its profitability. KRYS scores decently on growth, while it is valued quite cheap. This could make an interesting combination. These ratings could make KRYS a good candidate for value investing.


Dividend Valuation Growth Profitability Health

Quickly go to:

6

1. Profitability

1.1 Basic Checks

In the past year KRYS was profitable.
KRYS had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: KRYS reported negative net income in multiple years.
KRYS had negative operating cash flow in 4 of the past 5 years.
KRYS Yearly Net Income VS EBIT VS OCF VS FCFKRYS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M -150M

1.2 Ratios

Looking at the Return On Assets, with a value of 12.89%, KRYS belongs to the top of the industry, outperforming 95.45% of the companies in the same industry.
KRYS has a better Return On Equity (14.10%) than 94.36% of its industry peers.
The Return On Invested Capital of KRYS (12.87%) is better than 95.64% of its industry peers.
Industry RankSector Rank
ROA 12.89%
ROE 14.1%
ROIC 12.87%
ROA(3y)-5.09%
ROA(5y)-7.35%
ROE(3y)-5.33%
ROE(5y)-7.74%
ROIC(3y)N/A
ROIC(5y)N/A
KRYS Yearly ROA, ROE, ROICKRYS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

1.3 Margins

KRYS's Profit Margin of 40.85% is amongst the best of the industry. KRYS outperforms 98.36% of its industry peers.
KRYS's Operating Margin of 42.26% is amongst the best of the industry. KRYS outperforms 99.09% of its industry peers.
KRYS has a better Gross Margin (93.37%) than 94.18% of its industry peers.
Industry RankSector Rank
OM 42.26%
PM (TTM) 40.85%
GM 93.37%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KRYS Yearly Profit, Operating, Gross MarginsKRYS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

8

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so KRYS is still creating some value.
Compared to 1 year ago, KRYS has more shares outstanding
The number of shares outstanding for KRYS has been increased compared to 5 years ago.
KRYS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
KRYS Yearly Shares OutstandingKRYS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
KRYS Yearly Total Debt VS Total AssetsKRYS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

An Altman-Z score of 26.90 indicates that KRYS is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 26.90, KRYS belongs to the best of the industry, outperforming 95.64% of the companies in the same industry.
There is no outstanding debt for KRYS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 26.9
ROIC/WACC1.32
WACC9.77%
KRYS Yearly LT Debt VS Equity VS FCFKRYS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M 800M

2.3 Liquidity

KRYS has a Current Ratio of 9.68. This indicates that KRYS is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 9.68, KRYS is in the better half of the industry, outperforming 77.82% of the companies in the same industry.
A Quick Ratio of 9.33 indicates that KRYS has no problem at all paying its short term obligations.
KRYS has a better Quick ratio (9.33) than 76.55% of its industry peers.
Industry RankSector Rank
Current Ratio 9.68
Quick Ratio 9.33
KRYS Yearly Current Assets VS Current LiabilitesKRYS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 2794.12% over the past year.
The Revenue has grown by 116.08% in the past year. This is a very strong growth!
EPS 1Y (TTM)2794.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%143.4%
Revenue 1Y (TTM)116.08%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%36.65%

3.2 Future

Based on estimates for the next years, KRYS will show a very strong growth in Earnings Per Share. The EPS will grow by 56.83% on average per year.
The Revenue is expected to grow by 34.10% on average over the next years. This is a very strong growth
EPS Next Y92.44%
EPS Next 2Y76.95%
EPS Next 3Y66.14%
EPS Next 5Y56.83%
Revenue Next Year37.68%
Revenue Next 2Y43.58%
Revenue Next 3Y44%
Revenue Next 5Y34.1%

3.3 Evolution

KRYS Yearly Revenue VS EstimatesKRYS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
KRYS Yearly EPS VS EstimatesKRYS Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 20 40 60

More info and screens

8

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 29.19 indicates a quite expensive valuation of KRYS.
Based on the Price/Earnings ratio, KRYS is valued cheaper than 92.73% of the companies in the same industry.
KRYS's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 26.73.
The Price/Forward Earnings ratio is 15.34, which indicates a correct valuation of KRYS.
Based on the Price/Forward Earnings ratio, KRYS is valued cheaply inside the industry as 94.36% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 34.61, KRYS is valued rather cheaply.
Industry RankSector Rank
PE 29.19
Fwd PE 15.34
KRYS Price Earnings VS Forward Price EarningsKRYS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, KRYS is valued cheaper than 94.36% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, KRYS is valued cheaply inside the industry as 94.55% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 22.38
EV/EBITDA 19.87
KRYS Per share dataKRYS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30

4.3 Compensation for Growth

KRYS's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of KRYS may justify a higher PE ratio.
A more expensive valuation may be justified as KRYS's earnings are expected to grow with 66.14% in the coming years.
PEG (NY)0.32
PEG (5Y)N/A
EPS Next 2Y76.95%
EPS Next 3Y66.14%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for KRYS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

KRYSTAL BIOTECH INC

NASDAQ:KRYS (8/12/2025, 8:00:02 PM)

After market: 143.62 0 (0%)

143.62

+6.08 (+4.42%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-04 2025-08-04/bmo
Earnings (Next)11-03 2025-11-03/bmo
Inst Owners98.38%
Inst Owner Change0.24%
Ins Owners11.88%
Ins Owner Change-1.49%
Market Cap4.15B
Analysts84.44
Price Target210.21 (46.37%)
Short Float %12.7%
Short Ratio9.04
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.87%
Min EPS beat(2)-13.89%
Max EPS beat(2)12.14%
EPS beat(4)2
Avg EPS beat(4)6.3%
Min EPS beat(4)-13.89%
Max EPS beat(4)27.68%
EPS beat(8)3
Avg EPS beat(8)-4.07%
EPS beat(12)5
Avg EPS beat(12)-8.82%
EPS beat(16)7
Avg EPS beat(16)-7.79%
Revenue beat(2)1
Avg Revenue beat(2)-3.87%
Min Revenue beat(2)-10.17%
Max Revenue beat(2)2.42%
Revenue beat(4)1
Avg Revenue beat(4)-2.48%
Min Revenue beat(4)-10.17%
Max Revenue beat(4)2.42%
Revenue beat(8)4
Avg Revenue beat(8)8.28%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.43%
PT rev (3m)-5.11%
EPS NQ rev (1m)-2.18%
EPS NQ rev (3m)-28.82%
EPS NY rev (1m)0%
EPS NY rev (3m)-19.52%
Revenue NQ rev (1m)-1.15%
Revenue NQ rev (3m)-15.78%
Revenue NY rev (1m)-0.95%
Revenue NY rev (3m)-6.68%
Valuation
Industry RankSector Rank
PE 29.19
Fwd PE 15.34
P/S 11.56
P/FCF 22.38
P/OCF 21.24
P/B 3.99
P/tB 3.99
EV/EBITDA 19.87
EPS(TTM)4.92
EY3.43%
EPS(NY)9.36
Fwd EY6.52%
FCF(TTM)6.42
FCFY4.47%
OCF(TTM)6.76
OCFY4.71%
SpS12.43
BVpS36.01
TBVpS36.01
PEG (NY)0.32
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 12.89%
ROE 14.1%
ROCE 14.44%
ROIC 12.87%
ROICexc 36.62%
ROICexgc 36.62%
OM 42.26%
PM (TTM) 40.85%
GM 93.37%
FCFM 51.63%
ROA(3y)-5.09%
ROA(5y)-7.35%
ROE(3y)-5.33%
ROE(5y)-7.74%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score8
Asset Turnover0.32
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 159%
Cap/Sales 2.77%
Interest Coverage 250
Cash Conversion 123.63%
Profit Quality 126.39%
Current Ratio 9.68
Quick Ratio 9.33
Altman-Z 26.9
F-Score8
WACC9.77%
ROIC/WACC1.32
Cap/Depr(3y)534.57%
Cap/Depr(5y)974.6%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)2794.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%143.4%
EPS Next Y92.44%
EPS Next 2Y76.95%
EPS Next 3Y66.14%
EPS Next 5Y56.83%
Revenue 1Y (TTM)116.08%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%36.65%
Revenue Next Year37.68%
Revenue Next 2Y43.58%
Revenue Next 3Y44%
Revenue Next 5Y34.1%
EBIT growth 1Y3666.65%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year149.9%
EBIT Next 3Y73.68%
EBIT Next 5YN/A
FCF growth 1Y242.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y290.87%
OCF growth 3YN/A
OCF growth 5YN/A